Does delayed gastric emptying shorten the H pylori eradication period? A double blind clinical trial.
OBJECTIVE
To evaluate the gastric emptying inhibitory effects of sugar and levodopa on H pylori eradication period.


METHODS
A total of 139 consecutive patients were randomized into 6 groups. The participants with peptic ulcer disease or non-ulcer dyspepsia non-responding to other medications who were also H pylori-positive patients either with positive rapid urease test (RUT) or positive histology were included. All groups were pretreated with omeprazole for 2 d and then treated with quadruple therapy regimen (omeprazole, bismuth, tetracycline and metronidazole); all drugs were given twice daily. Groups 1 and 2 were treated for 3 d, groups 3, 4 and 5 for 7 d, and group 6 for 14 d. Groups 1 to 4 received sugar in the form of 10% sucrose syrup. Levodopa was prescribed for groups 1 and 3. Patients in groups 2 and 4 were given placebo for levodopa and groups 5 and 6 received placebos for both sugar and levodopa. Upper endoscopy and biopsies were carried out before treatment and two months after treatment. Eradication of H pylori was assessed by RUT and histology 8 wk later.


RESULTS
Thirty patients were excluded. Per-protocol analysis showed successful eradication in 53% in group 1, 56% in group 2, 58% in group 3, 33.3% in group 4, 28% in group 5, and 53% in group 6. Eradication rate, patient compliance and satisfaction were not significantly different between the groups.


CONCLUSIONS
It seems that adding sugar or levodopa or both to anti H pylori eradication regimens may lead to shorter duration of treatment.
Emami
Mohammad Hassan
MH
Isfahan University of Medical Sciences, Poursina Hakim Research Institute, Mail box: 81465-1798, Isfahan, Iran. mh_emami@med.mui.ac.ir
Saberfiroozi
Mohammad Mehdi
MM
Arj
Abbas
A
Taghavi
Ali Reza
AR
Bagheri-Lankarani
Kamran
K
Dehbashi
Najaf
N
Fattahi
Mohammad Reza
MR
Alizadeh
Mahvash
M
Kaviani
Mohammad Javad
MJ
Bahri-Najafi
Rahim
R
Geramizadeh
Bita
B
Esmaeili
Abbas
A
D000863:Antacids / Q000494:pharmacology / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000494:pharmacology* / Q000627:therapeutic use*; D000890:Anti-Infective Agents / Q000494:pharmacology / Q000627:therapeutic use; D000897:Anti-Ulcer Agents / Q000494:pharmacology / Q000627:therapeutic use; D001729:Bismuth / Q000494:pharmacology / Q000627:therapeutic use; D015259:Dopamine Agents / Q000494:pharmacology; D004311:Double-Blind Method; D004415:Dyspepsia / Q000188:drug therapy / Q000209:etiology; D005746:Gastric Emptying / Q000187:drug effects / Q000502:physiology*; D016481:Helicobacter Infections / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D016480:Helicobacter pylori / Q000187:drug effects*; D006801:Humans; D007980:Levodopa / Q000494:pharmacology*; D008795:Metronidazole / Q000494:pharmacology / Q000627:therapeutic use; D009853:Omeprazole / Q000494:pharmacology / Q000627:therapeutic use; D010437:Peptic Ulcer / Q000188:drug therapy / Q000209:etiology; D013395:Sucrose / Q000494:pharmacology*; D013752:Tetracycline / Q000494:pharmacology / Q000627:therapeutic use; D016896:Treatment Outcome
D000863:Antacids; D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents; D000897:Anti-Ulcer Agents; D015259:Dopamine Agents; D008795:Metronidazole; D007980:Levodopa; D013395:Sucrose; D013752:Tetracycline; D009853:Omeprazole; D001729:Bismuth